33 results on '"Yassin, Aksam"'
Search Results
2. IS THERE A PROTECTIVE ROLE OF TESTOSTERONE AGAINST HIGH-GRADE PROSTATE CANCER? INCIDENCE AND SEVERITY OF PROSTATE CANCER IN 553 PATIENTS UNDERGOING PROSTATE BIOPSY IN A PROSPECTIVE DATA REGISTER: PD50-05
3. PREDIABETES, HYPOGONADISM & ERECTILE DYSFUNCTION: GLYCAEMIC CONTROL IN 109 HYPOGONADAL MEN TREATED WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) FOR UP TO 8 YEARS: REAL-LIFE DATA FROM REGISTRY STUDIES: MP47-07
4. PD45-06 LONG-TERM EFFECTS ON ERECTILE FUNCTION UPON TREATMENT UP TO 11 YEARS WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) IN HYPOGONADAL MEN WITH TYPE 2 DIABETES MELLITUS (T2DM): REAL-LIFE DATA FROM AN OBSERVATIONAL REGISTRY STUDY
5. MP27-03 EFFECTS OF CONTINUOUS LONG-TERM TESTOSTERONE REPLACEMENT THERAPY (TRT) UP TO 11 YEARS IN 115 HYPOGONADAL ELDERLY MEN ON ANTHROPOMETRIC, ENDOCRINE AND METABOLIC PARAMETERS: REAL-LIFE EXPERIENCE FROM AN OBSERVATIONAL REGISTRY STUDY
6. LONG-TERM TESTOSTERONE TREATMENT LEADS TO PROGRESSIVE WEIGHT LOSS AND WAIST SIZE REDUCTION IN HYPOGONADAL MEN: MP48-01
7. 162 HYPOGONADAL MEN WITH OBESITY RESPOND TO LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE WITH UNEXPECTED WEIGHT LOSS: MP32-17
8. TESTOSTERONE REPLACEMENT THERAPY IMPROVES THE QUALITY OF LIFE OF HYPOGONADAL MEN DIAGNOSED WITH “LATE ONSET HYPOGONADISM” – ASSESSED BY VALIDATED QUESTIONNAIRES: MP32-18
9. COMPLETING FIVE YEARS OF TESTOSTERONE TREATMENT LEADS TO PROGRESSIVE WEIGHT LOSS AND WAIST SIZE REDUCTION AS WELL AS IMPROVEMENT OF METABOLIC SYNDROME PARAMETERS IN MEN WITH LATE ONSET HYPOGONADISM (LOH): MP32-12
10. EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS IN HYPOGONADAL MEN ON WAIST CIRCUMFERENCE, BODY WEIGHT AND BMI: 1400
11. FROM WHICH SERUM TESTOSTERONE LEVEL SHOULD WE ADD TESTOSTERONE THERAPY TO MEN WITH ERECTILE DYSFUNCTION NOT RESPONDING TO PDE5 INHIBITORS ALONE? A DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF TESTOSTERONE GEL ADDITION TO MEN NOT RESPONDING TO TADALAFIL ONCE A DAY ALONE: 1367
12. TESTOSTERONE TREATMENT IN HYPOGONADAL PATIENTS DOES NOT CAUSE HIGHER INCIDENCE OF PROSTATE CANCER: 870
13. PD27-09 IMPROVEMENT OF SEXUAL FUNCTIONS, METABOLIC SYNDROME COMPONENTS AND REDUCED INFLAMMATION UNDER LONG-TERM TREATMENT IN HYPOGONADAL MEN FOR UP TO 14 YEARS: REAL-LIFE DATA FROM A REGISTRY STUDY
14. MP91-11 POSITIVE EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) ON RENAL FUNCTION IN HYPOGONADAL MEN: REAL-LIFE DATA FROM A PROSPECTIVE CONTROLLED REGISTRY STUDY
15. MP91-14 CARDIOVASCULAR DISEASE (CVD), HYPOGONADISM & ED: POSITIVE EFFECTS UNDER LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU)
16. PD45-03 VOIDING FUNCTION IMPROVES UNDER LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) IN HYPOGONADAL MEN FOR UP TO 12 YEARS INDEPENDENT OF PROSTATE SIZE
17. PD45-01 CHANGE OF CATEGORIES OF THE INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS) IN HYPOGONADAL PATIENTS WITH AND WITHOUT TESTOSTERONE THERAPY FOR UP TO 12 YEARS: REAL-WORLD DATA FROM TWO POOLED CONTROLLED REGISTRY STUDIES
18. PD50-05 IS THERE A PROTECTIVE ROLE OF TESTOSTERONE AGAINST HIGH-GRADE PROSTATE CANCER? INCIDENCE AND SEVERITY OF PROSTATE CANCER IN 553 PATIENTS UNDERGOING PROSTATE BIOPSY IN A PROSPECTIVE DATA REGISTER
19. MP47-07 PREDIABETES, HYPOGONADISM & ERECTILE DYSFUNCTION: GLYCAEMIC CONTROL IN 109 HYPOGONADAL MEN TREATED WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) FOR UP TO 8 YEARS: REAL-LIFE DATA FROM REGISTRY STUDIES
20. MP48-01 LONG-TERM TESTOSTERONE TREATMENT LEADS TO PROGRESSIVE WEIGHT LOSS AND WAIST SIZE REDUCTION IN HYPOGONADAL MEN
21. MP32-17 162 HYPOGONADAL MEN WITH OBESITY RESPOND TO LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE WITH UNEXPECTED WEIGHT LOSS
22. MP32-18 TESTOSTERONE REPLACEMENT THERAPY IMPROVES THE QUALITY OF LIFE OF HYPOGONADAL MEN DIAGNOSED WITH “LATE ONSET HYPOGONADISM” – ASSESSED BY VALIDATED QUESTIONNAIRES
23. MP32-12 COMPLETING FIVE YEARS OF TESTOSTERONE TREATMENT LEADS TO PROGRESSIVE WEIGHT LOSS AND WAIST SIZE REDUCTION AS WELL AS IMPROVEMENT OF METABOLIC SYNDROME PARAMETERS IN MEN WITH LATE ONSET HYPOGONADISM (LOH)
24. 1400 EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS IN HYPOGONADAL MEN ON WAIST CIRCUMFERENCE, BODY WEIGHT AND BMI
25. 1493 LOWER URINARY TRACT SYMPTOMS IMPROVE WITH TESTOSTERONE REPLACEMENT THERAPY IN MEN WITH LATE ONSET HYPOGONADISM
26. 1491 LONG-TERM TESTOSTERONE IMPROVES ALL THE DOMAINS OF METABOLIC SYNDROME
27. 1492 TESTOSTERONE REPLACEMENT THERAPY IMPROVES GLUCOSE CONTROL THROUGH WEIGHT LOSS AND WAIST CIRCUMFERENCE REDUCTION
28. 1151 TESTOSTERONE REPLACEMENT THERAPY WITH TESTOSTERONE UNDECANOATE LONG ACTING INTRAMUSCULAR INJECTIONS IS ASSOCIATED WITH REDUCTION IN OBESITY
29. 372 TESTOSTERONE TREATMENT IN ELDERLY HYPOGONADAL PATIENTS DOES NOT INCREASE PROSTATE CANCER RISK RESULTS OF A PROSPECTIVE COMPARATIVE STUDY. 7 YEARS FOLLOW UP ANALYSIS TO AGE-MATCHED CONTROLS
30. 1673 RESTORING ERECTILE FUNCTION IN HYPOGONADAL ELDERLY PATIENTS WHO FAILED TO RESPOND TO TESTOSTERONE TREATMENT ALONE, UPON COMBINATION WITH VARDENAFIL
31. 863: Erectile Dysfunction, Metabolic Syndrome, Hypogonadism are Intertwined
32. 1196: Effects of Androgen Deprivation on Glycemic Control and on Biochemical Cardiovascular Risk Factors in Men with Diabetes
33. 521: Oral Desmopressin in the Treatment of Nocturia in Aging Population
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.